MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:33Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Bisphosphonates]]
			[[Category:Antiresorptives]]
			[[Category:Osteoporosis medications]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #113

2026-05-23T03:46:16Z

parser-claude batch MedTemplate pre-fill, Top 300 #113

New page

{{MedTemplate
| generic = Alendronate
| brand = Fosamax, Binosto
| structure =
| classes = [[:Category:Bisphosphonates|Bisphosphonate (nitrogen-containing)]], [[:Category:Antiresorptives|Antiresorptive]], [[:Category:Osteoporosis_medications|Osteoporosis medication]]
| uses = <vote slug="osteoporosis-treatment-use">Osteoporosis treatment (postmenopausal, male, glucocorticoid-induced)</vote>, <vote slug="osteoporosis-prevention-use">Osteoporosis prevention</vote>, <vote slug="paget-disease-use">Paget's disease of bone</vote>
| starting_dose = Treatment 70 mg PO once weekly (or 10 mg daily); prevention 35 mg weekly (or 5 mg daily); always taken first thing in the morning with a full glass of water, remaining upright for 30 minutes
| preparations = 5, 10, 35, 40, 70 mg tablets; 70 mg/75 mL oral solution; 70 mg effervescent (Binosto)
| fda_max = 70 mg/week treatment; 40 mg/d for 6 months in Paget's
| pill_id =
| routes = Oral
| onset = Bone marker reduction within weeks; BMD improvement at 1-3 years; fracture-risk reduction documented at 3-5 years
| duration = Weeks; bone retention years
| halflife = Plasma ~3 hours; bone half-life ~10 years<ref name="fosamax-label">FDA Prescribing Information, Fosamax (alendronate sodium), Merck, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020560s045lbl.pdf</ref>
| bioavailability = <1% (oral; further reduced by food, calcium, iron, antacids; hence the strict fasting/upright dosing rules)<ref name="fosamax-label" />
| pregnancy = Long-term skeletal retention is a concern given the unknown effect on developing fetal bone; generally avoided.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="alendronate-mech-claim">Alendronate is a nitrogen-containing bisphosphonate that adsorbs to hydroxyapatite at sites of active bone remodeling, is taken up by osteoclasts during resorption, and inhibits farnesyl pyrophosphate synthase in the mevalonate pathway; loss of prenylation impairs osteoclast cytoskeleton and ruffled border, slowing bone resorption and shifting net remodeling toward formation.</vote> Drug-holiday concept (3-5 years on, 1-2 years off) emerged from FLEX and long-term safety data balancing fracture protection against atypical femoral fracture and osteonecrosis of the jaw signals<ref name="fosamax-label" />.
}}

== References ==
<references />

Alendronate - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #113